当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.

Initial potency of lansoprazole and omeprazole tablets on pentagastrin-stimulated gastric acid secretion-a placebo-controlled study in healthy volunteers.

Abstract：

BACKGROUND:The new tablet formulation of omeprazole (Losec MUPS), is thought to have a stronger acid inhibition than the previously marketed capsules. METHODS:The effects of the proton pump inhibitors lansoprazole and omeprazole tablets on pentagastrin-stimulated acid secretion were compared in Helicobacter pylori-negative healthy male volunteers (n=12). The study was placebo-controlled, crossover matched and double-blind for lansoprazole (Agopton) and placebo, and single-blind for omeprazole tablets. Gastric acid response to sub-maximal pentagastrin-stimulation (0.6 microg. h/kg b.w.) was determined from 12.5 to 14.5 h after the first and second dose of the test drugs. RESULTS:Lansoprazole 15 mg and 30 mg as well as omeprazole 20 mg tablets caused a marked decrease in gastric acid secretion, showing equipotency for 15 mg lansoprazole and 20 mg omeprazole tablets. Their efficacy, however, was lower than 30 mg lansoprazole. In addition, the inter-individual variation after omeprazole tablets was higher than following lansoprazole. Neither 7.5 mg lansoprazole nor 10 mg omeprazole tablets were clearly different from placebo on the first 2 days. The drugs were well-tolerated. No clinically relevant influence was found on either laboratory screen or cardiovascular parameters. CONCLUSION:Lansoprazole 15-30 mg shows a stronger acid inhibition and a lower inter-individual variability than the new omeprazole 20 mg tablets on days 1 and 2 of dosing.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Müller P,Göksu MA,Fuchs W,Schlüter F,Simon B

doi

10.1046/j.1365-2036.2000.00823.x

subject

Has Abstract

pub_date

2000-09-01 00:00:00

pages

1225-9

issue

9

eissn

0269-2813

issn

1365-2036

pii

apt823

journal_volume

14

pub_type

临床试验,杂志文章

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.

    abstract：BACKGROUND:The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough concentrations and loss of response. IFX treatment intensification is effective for restoring response in most, but not all patients with Crohn's disease (CD). AIM:To compare outcome, pharmacokinetics and im...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.14452

    authors： Dreesen E,Van Stappen T,Ballet V,Peeters M,Compernolle G,Tops S,Van Steen K,Van Assche G,Ferrante M,Vermeire S,Gils A

    更新日期：2018-02-01 00:00:00

  • Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.

    abstract：BACKGROUND:One-week low-dose proton pump inhibitor-based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection. AIM:To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluo...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1046/j.1365-2036.2000.00846.x

    authors： Cammarota G,Cianci R,Cannizzaro O,Cuoco L,Pirozzi G,Gasbarrini A,Armuzzi A,Zocco MA,Santarelli L,Arancio F,Gasbarrini G

    更新日期：2000-10-01 00:00:00

  • Circadian differences in pharmacological blockade of meal-stimulated gastric acid secretion.

    abstract：:The effects of identical morning (08.05 hours) and evening (20.05 hours) meals on intragastric pH were compared in 12 healthy volunteers receiving gastric antisecretory medication. Dosing included continuous intravenous infusion ranitidine (50 mg bolus followed by 12.5 mg/h) or a matching placebo which were randomly a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1992.tb00262.x

    authors： Sanders SW,Moore JG,Day GM,Tolman KG

    更新日期：1992-04-01 00:00:00

  • Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.

    abstract：BACKGROUND:The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available. AIM:To compare the efficacy of terlipressin plus albumin vs. placebo plus albumin in p...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1111/apt.14052

    authors： Sanyal AJ,Boyer TD,Frederick RT,Wong F,Rossaro L,Araya V,Vargas HE,Reddy KR,Pappas SC,Teuber P,Escalante S,Jamil K

    更新日期：2017-06-01 00:00:00

  • Effect of mefenamic acid on bowel transit time in healthy adult volunteers.

    abstract：:The effect of mefenamic acid on bowel transit time was investigated. Seven healthy adult male subjects of age 39 +/- 2.4 years (mean +/- S.E.M.) received placebo or mefenamic acid (500 mg t.d.s) orally in randomized order for five days, with a 7-day washout between studies. On the third morning after starting the drug...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1990.tb00488.x

    authors： Rashid MU,Bateman DN

    更新日期：1990-08-01 00:00:00

  • Classification of dyspepsia and response to treatment with proton-pump inhibitors.

    abstract：BACKGROUND:Lacking an objective 'gold standard' for diagnosing dyspepsia, several symptom-based classifications have been suggested. AIM:To assess if response to proton-pump inhibitor treatment could provide useful information for current or future dyspepsia classification. METHODS:Post hoc analyses of 829 patients t...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2004.02243.x

    authors： Meineche-Schmidt V

    更新日期：2004-11-15 00:00:00

  • Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.

    abstract：BACKGROUND:Hepatocellular carcinoma (HCC) risk after resolving chronic hepatitis B virus (HBV) infection is unclear. AIM:To compare HCC risk between Alaska Native (AN) patients with and without hepatitis B surface antigen (HBsAg) seroclearance. METHODS:We selected persons with (case-patients) and without (control-pat...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13621

    authors： Gounder PP,Bulkow LR,Snowball M,Negus S,Spradling PR,Simons BC,McMahon BJ

    更新日期：2016-06-01 00:00:00

  • Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

    abstract：AIM:: To quantify through systematic review the pharmacokinetic profiles of the oral delayed release and sustained release mesalazine (5-aminosalicylate, 5ASA) formulations (Asacol, Salofalk, Mesasal, Claversal, Pentasa) and pro-drugs (sulfasalazine, olsalazine, balsalazide) used in the management of ulcerative colitis...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2003.01408.x

    authors： Sandborn WJ,Hanauer SB

    更新日期：2003-01-01 00:00:00

  • Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy.

    abstract：BACKGROUND:Subtotal or total colectomy or proctocolectomy with permanent ileostomy (TC-PI) may be a treatment option for medically refractory colonic Crohn's disease (CD). AIM:To perform a systematic review and meta-analysis to evaluate the rate, risk factors and outcomes of CD recurrence after TC-PI. METHODS:In a sy...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析,评审

    doi：10.1111/apt.13886

    authors： Fumery M,Dulai PS,Meirick P,Farrell AM,Ramamoorthy S,Sandborn WJ,Singh S

    更新日期：2017-02-01 00:00:00

  • Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group.

    abstract：:In a double-blind parallel-group study, 98 patients with symptomatic duodenal ulcer received omeprazole 20 mg o.m. and 91 cimetidine 800 mg nocte for 2 or, if then not healed, 4 weeks. After 2 weeks the healing rates on an intention-to-treat basis were: for omeprazole 62% and for cimetidine 33% (P less than 0.001), an...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1989.tb00193.x

    authors： Crowe JP,Wilkinson SP,Bate CM,Willoughby CP,Peers EM,Richardson PD

    更新日期：1989-02-01 00:00:00

  • Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density.

    abstract：BACKGROUND:Several studies have explored the effect of non-alcoholic fatty liver disease (NAFLD) on bone mineral density (BMD) and risk of osteoporotic fractures in adults. However, the extent to which NAFLD adversely affects bone health remains uncertain. AIM:To provide a quantitative estimation of the magnitude of t...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1111/apt.15087

    authors： Mantovani A,Dauriz M,Gatti D,Viapiana O,Zoppini G,Lippi G,Byrne CD,Bonnet F,Bonora E,Targher G

    更新日期：2019-02-01 00:00:00

  • Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.

    abstract：BACKGROUND:Adverse events leading to discontinuation or dose reduction of thiopurine therapy occur in 9-28% of patients with inflammatory bowel disease. AIMS:To evaluate the influence of thiopurine methyltransferase status and thiopurine metabolites in a large patient population for the risk of developing adverse even...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2006.02977.x

    authors： Hindorf U,Lindqvist M,Hildebrand H,Fagerberg U,Almer S

    更新日期：2006-07-15 00:00:00

  • Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.

    abstract：BACKGROUND:Adalimumab is effective in inducing remission in patients with active Crohn's disease who had secondary failure to infliximab therapy. AIM:To evaluate the efficacy and safety of adalimumab maintenance therapy in Crohn's disease patients who previously responded to infliximab and then lost response or became...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.2007.03254.x

    authors： Peyrin-Biroulet L,Laclotte C,Bigard MA

    更新日期：2007-03-15 00:00:00

  • Review article: the treatment of hepatitis C virus recurrence after liver transplantation.

    abstract：BACKGROUND:Recurrent hepatitis C represents a major challenge for the liver transplant community. Given the potentially significant impact that hepatitis C recurrence has on graft and patient survival, several treatment strategies have been utilized to prevent/slow the progression to hepatitis C-related graft failure. ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2007.03364.x

    authors： Arjal RR,Burton JR Jr,Villamil F,Rosen HR

    更新日期：2007-07-15 00:00:00

  • Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.

    abstract：BACKGROUND:One-week triple therapy consisting of omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. is an effective therapy for H. pylori infection with a cure rate of 93%. We therefore compared two similar 1-week regimens consisting of a lansoprazole, clarithromycin and either metronidazole o...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.0953-0673.1996.00275.x

    authors： Jaup BH,Norrby A

    更新日期：1996-06-01 00:00:00

  • Effect of treatment with liu-jun-zi-tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients.

    abstract：:The effects of treatment with the Chinese herbal medicine Liu-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms were investigated in 42 patients with chronic idiopathic dyspepsia. By random allocation, 22 patients received oral treatment with 2.5 g TJ-43 three times daily, and 20 patients received ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1993.tb00120.x

    authors： Tatsuta M,Iishi H

    更新日期：1993-08-01 00:00:00

  • Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.

    abstract：BACKGROUND:Efficacy and safety of antiviral combination therapy in patients with Crohn's disease (CD) and chronic hepatitis C (CHC) is presently not established and consequently CHC is rarely treated in CD patients. AIM:To analyse the efficacy and tolerability of antiviral interferon/ribavirin therapy in patients with...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03779.x

    authors： Scherzer TM,Staufer K,Novacek G,Steindl-Munda P,Schumacher S,Hofer H,Ferenci P,Vogelsang H

    更新日期：2008-09-15 00:00:00

  • Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs.

    abstract：:Candidiasis of the oropharynx and oesophagus is one of the most common problems encountered in patients with HIV disease. Fluconazole is a bis-triazole antifungal agent with a long serum half-life. Sixteen anti-HIV positive patients (15 haemophiliacs and one blood transfusion recipient) with a clinical diagnosis of or...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1991.tb00021.x

    authors： Lim SG,Lee CA,Hales M,O'Doherty M,Winter M,Kernoff PB

    更新日期：1991-04-01 00:00:00

  • Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy.

    abstract：BACKGROUND:Current guidelines recommend the cessation of clopidogrel therapy 5 days and 7-10 days prior to colonoscopic polypectomy. Recent studies have advocated for continued clopidogrel as post-polypectomy bleeding (PPB) rates have been similar to those in the general population not on antithrombotic therapy. AIM:T...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1111/apt.12292

    authors： Gandhi S,Narula N,Mosleh W,Marshall JK,Farkouh M

    更新日期：2013-05-01 00:00:00

  • Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre.

    abstract：BACKGROUND:Hepatitis vaccination is recommended in patients with chronic liver disease. AIM:To validate Current Procedural Terminology (CPT) codes and drug codes for hepatitis vaccination in administrative databases and determine vaccination rates in hepatitis C virus (HCV)-infected patients in a single large Veterans...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03827.x

    authors： Hachem CY,Kramer JR,Kanwal F,El-Serag HB

    更新日期：2008-11-01 00:00:00

  • Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer.

    abstract：BACKGROUND:Helicobacter pylori eradication has become the standard treatment for duodenal ulcer. However, there is no relevant evidence for antibacterial treatment of the white scar stage of duodenal ulcer (duodenal ulcer scar) in patients with no past history of duodenal ulcer. AIM:To investigate whether H. pylori er...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2002.01174.x

    authors： Kim JS,Kim SG,Choi IJ,Park MJ,Kim BG,Jung HC,Song IS

    更新日期：2002-02-01 00:00:00

  • Review article: Inflammatory bowel disease and genetics.

    abstract：INTRODUCTION:Inflammatory bowel disease (IBD) comprising ulcerative colitis (UC) and Crohn's disease (CD) is multigenic disorder. Tremendous progress has been achieved in unravelling the genetic background of IBD. It has led to the discovery of mutations in NOD2 associated with ileal CD and numerous other genes have be...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2007.03476.x

    authors： Weersma RK,van Dullemen HM,van der Steege G,Nolte IM,Kleibeuker JH,Dijkstra G

    更新日期：2007-12-01 00:00:00

  • The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C.

    abstract：BACKGROUND:Studies have shown that past alcohol consumption reduces response rates in patients with chronic hepatitis C treated with interferon monotherapy. AIM:To clarify the importance of alcohol consumption on response rates in patients undergoing treatment with pegylated interferon and ribavirin. METHODS:In a sin...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2005.02631.x

    authors： Chang A,Skole K,Gautam M,Schmutz J,Black M,Thomas R,Horwitz B,Friedenberg FK

    更新日期：2005-10-15 00:00:00

  • Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?

    abstract：BACKGROUND:The presence of the gastric pathogen, Helicobacter pylori influences acid suppression by proton pump inhibitors and treatment outcome in patients with gastro-oesophageal reflux disease. AIM:To determine the influence of H. pylori infection on effectiveness of rabeprazole in primary and secondary care patien...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2004.02096.x

    authors： Wit NJ,Boer WA,Geldof H,Hazelhoff B,Bergmans P,Tytgat GN,Smout AJ

    更新日期：2004-08-15 00:00:00

  • Double stenting of oesophagus and airways in palliative treatment of patients with oesophageal cancer is efficient but associated with a high morbidity.

    abstract：BACKGROUND:Double stenting of oesophagus and airways may be required in palliative treatment of patients with locally advanced oesophageal cancer. AIM:To assess feasibility, efficacy and complications occurring in patients with locally advanced oesophageal cancer receiving both oesophagus and airways stenting. METHOD...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2007.03280.x

    authors： Lecleire S,Antonietti M,Di Fiore F,Ben-Soussan E,Bota S,Hellot MF,Thiberville L,Michel P,Lerebours E,Ducrotté P

    更新日期：2007-04-15 00:00:00

  • Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even

    abstract：BACKGROUND:The large (n = 18 325) Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) study demonstrated a significant gastrointestinal benefit with lumiracoxib 400 mg o.d. (4x the recommended dose in osteoarthritis) vs. naproxen 500 mg b.d. or ibuprofen 800 mg t.d.s. AIM:To investigate how early ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2008.03622.x

    authors： Hawkey CJ,Weinstein WM,Stricker K,Murphy V,Richard D,Krammer G,Rebuli R

    更新日期：2008-05-01 00:00:00

  • Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study.

    abstract：BACKGROUND:Gastroprotective strategies are recommended for nonsteroidal anti-inflammatory drug (NSAID) users at risk of upper gastrointestinal (UGI) complications. AIM:To compare the use of gastroprotective strategies in NSAID users in three countries, and the subsequent impact of rofecoxib withdrawal. METHODS:We con...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12028

    authors： Valkhoff VE,van Soest EM,Masclee GM,de Bie S,Mazzaglia G,Molokhia M,Kuipers EJ,Sturkenboom MC

    更新日期：2012-10-01 00:00:00

  • Review article: anti-adhesion therapies for inflammatory bowel disease.

    abstract：BACKGROUND:A high proportion of patients with inflammatory bowel disease (IBD) do not achieve clinical remission with the current therapies including mesalazine (mesalamine), immunossupresants (IMS) and antibodies against tumour necrosis factor (anti-TNF). Moreover, IMS and anti-TNF involve a nonnegligible risk for inf...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12639

    authors： Lobatón T,Vermeire S,Van Assche G,Rutgeerts P

    更新日期：2014-03-01 00:00:00

  • Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection.

    abstract：AIM:To compare the efficacy of ranitidine bismuth citrate plus clarithromycin (RBC-C) vs. omeprazole plus amoxycillin (OME-AMO) in the cure of Helicobacter pylori infection. METHODS:In this double-blind, multicentre, parallel-group study 122 H. pylori-positive patients with active duodenal ulcer or gastritis, with con...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1997.00254.x

    authors： Kolkman JJ,Tan TG,Oudkerk Pool M,Van Kleef WA,Geraedts AA,Timmerman RJ,Crobach LF,Nicolai JJ,Wolff AA,Van Der Laan J

    更新日期：1997-12-01 00:00:00

  • Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori.

    abstract：BACKGROUND:The success of eradication therapy for Helicobacter pylori might be affected by the age of patients. AIM:To investigate whether disposition of drugs commonly used for H. pylori eradication is age-dependent. METHODS:Trough steady state serum levels of lansoprazole or ranitidine, amoxycillin, clarithromycin ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2000.00756.x

    authors： Ammon S,Treiber G,Kees F,Klotz U

    更新日期：2000-06-01 00:00:00